Abstract:Abstract It has been more than 10 years since the hopes for disease modeling and drug discovery using induced pluripotent stem cell (iPSC) technology boomed. Recently, clinical trials have been conducted with drugs identified using this technology, and some promising results have been reported. For amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, several groups have identified candidate drugs, ezogabine (retigabine), bosutinib, and ropinirole, using iPSCs‐based drug discovery, and clinical trials using these drugs have been conducted, yielding interesting results. In our previous study, an iPSCs‐based drug repurposing approach was utilized to show the potential of ropinirole hydrochloride (ROPI) in reducing ALS‐specific pathological phenotypes. Recently, a phase 1/2a trial was conducted to investigate the effects of ropinirole on ALS further. This double‐blind, randomized, placebo‐controlled study confirmed the safety and tolerability of and provided evidence of its ability to delay disease progression and prolong the time to respiratory failure in ALS patients. Furthermore, in the reverse translational research, in vitro characterization of patient‐derived iPSCs‐motor neurons (MNs) mimicked the therapeutic effects of ROPI in vivo, suggesting the potential application of this technology to the precision medicine of ALS. Interestingly, RNA‐seq data showed that ROPI treatment suppressed the sterol regulatory element‐binding protein 2‐dependent cholesterol biosynthesis pathway. Therefore, this pathway may be involved in the therapeutic effect of ROPI on ALS. The possibility that this pathway may be involved in the therapeutic effect of ALS was demonstrated. Finally, new future strategies for ALS using iPSCs technology will be discussed in this paper.

iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases

Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling

Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery

Human-induced pluripotent stem cells: potential for neurodegenerative diseases

iPSC for modeling neurodegenerative disorders

Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: Mirage or reality?

Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening

Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges

[iPS cell technologies toward overcoming neurological diseases]

Modeling Alzheimer’s disease with iPSC-derived brain cells

Advances in the Application of Induced Pluripotent Stem Cells in Alzheimer's Disease and Parkinson's Disease

Recent advances of induced pluripotent stem cells application in neurodegenerative diseases

Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery

CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics

Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation

Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis

Induced pluripotent stem cells for neural drug discovery

Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders